Skip to main content

Table 5 Growth factors for external using products approved for marketing by the SFDA

From: Regenerative medicine in China: main progress in different fields

Company Time Products Effect Status
Zhuhai Essex Bio-Pharmaceutical 1998 Recombinant bovine basic fibroblast growth factor Burn and scald wounds: including shallow II degree and deep II degree wounds, granulation wounds and inhalation injuries.
* Acute wounds: bruises, contusions, combined injuries and cuts.
* Surgical incisions: incisions of surgery, orthopedics, gynaecology (such as lateral episiotomy and cesarean incision), otolaryngology, urology and proctology.
* Chronic wounds: diabetic ulcers, vascular ulcers, radiochemotherapy ulcers, bedsores, fistulas, residual wounds and cervical erosions.
* Skin grafting: skin donor site, skin grafting site, skin flap handling.
* Other applications: after plastic surgery, skin resurfacing, dermabrasion, nevus removal and laser therapy wounds.
SFDA Approval No.S10980077
1999 Recombinant bovine basic fibroblast growth factor Eye Drops * Various corneal defects and punctate keratopathy.
* Recurrent punctate keratopathy in the shallow layer.
* Mild or moderate dry eye.
* Corneal operation and poor corneal healing after operation.
* Geographic (or nutritional) herpes simplex keratitis.
* Ballous keratitis.
* Corneal abrasion, mild and moderate chemical burns.
SFDA Approval No.S19991022
2005 Recombinant bovine basic fibroblast growth factor Gel Treatment of various keratopathy, ocular traumas and foreign body removal.
* Corneal transplantation and eye surface reconstruction.
* Dry eye: especially dry eye due to corneal injury.
* Cataract surgery (ECCE. Phaco etc.): restoration of endothelium and reduction of edema.
* Corneal refractive surgery: repair damaged corneas before surgery, repair damaged nerves after surgery and treat postoperative dry eye
SFDA Approval No.S20050100
Beijing SL Pharmaceutical 2002 Lyophilized Recombinant Human Basic Fibroblast Growth Factor (rh-bFGF) Chronic Cutaneous Ulcer and Burn Wounds SFDA Approval No.S20020025
Nanhai Longtime Pharmaceutical 2004 Recombinant Human Basic Fibroblast Growth Factor for External Use Chronic Cutaneous Ulcer and Burn Wounds SFDA Approval No.S20040052
Shanghai Wanxing Bio-Pharmaceutical 2006 Lyophilized Recombinant Human Acidic Fibroblast Growth Factor For External Use Chronic Cutaneous Ulcer and Burn Wounds SFDA Approval No.S20060102
Guilin pavay gene Pharmaceutical 2002 Recombinant Human Epidermal Growth Factor Hydro Gel Chronic Cutaneous Ulcer and Burn Wounds SFDA Approval No.S20020111
Wuhan HITECK biological pharmaceutical 2006 Mouse nerve growth factor for injection Peripheral nerve injury and peripheral neuropathy; Brain and spinal cord injury; Acute cerebrovascular disease, cerebral atrophy, Parkinson’s and Alzheimer’s disease. SFDA Approval No.S20060051